deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00863538

Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

An Open-label, Phase II Study of KPS-0373 in Patients With SCD

Sponsor: Kissei Pharmaceutical Co., Ltd.

Conditions Spinocerebellar Degeneration
Interventions KPS-0373
Updated 5 times since 2017 Last updated: Feb 1, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Spinocerebellar Degeneration and is currently completed. Kissei Pharmaceutical Co., Ltd. leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Kissei Pharmaceutical Co., Ltd.
Data source: Kissei Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations